Education
About Us
Working with TipRanks
Follow Us
Kuros Biosciences (CH:KURN)
:KURN
Total Valuation
Kuros Biosciences has a market cap or net worth of CHF1.13B. The enterprise value is CHF1.03B.
Market CapCHF1.13B
Enterprise ValueCHF1.03B
Share Statistics
Kuros Biosciences has 39,152,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,152,830
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kuros Biosciences’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -8.57%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-8.57%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee619.30K
Profits Per Employee-32.13K
Employee Count122
Asset Turnover0.89
Inventory Turnover1.43
Valuation Ratios
The current PE Ratio of Kuros Biosciences is ―. Kuros Biosciences’s PEG ratio is 2.90.
PE Ratio―
PS Ratio10.51
PB Ratio13.52
Price to Fair Value13.52
Price to FCF391.61
Price to Operating Cash Flow1.36K
PEG Ratio2.90
Income Statement
In the last 12 months, Kuros Biosciences had revenue of 75.56M and earned -3.72M in profits. Earnings per share was -0.10.
Revenue75.56M
Gross Profit62.03M
Operating Income-5.00M
Pretax Income-3.35M
Net Income-3.72M
EBITDA-561.00K
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was 779.00K and capital expenditures -1.57M, giving a free cash flow of -787.00K billion.
Operating Cash Flow779.00K
Free Cash Flow-787.00K
Free Cash Flow per Share-0.02
Dividends & Yields
Kuros Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change36.76%
50-Day Moving Average28.04
200-Day Moving Average25.23
Relative Strength Index (RSI)63.12
Average Volume (3m)214.85K
Important Dates
Kuros Biosciences upcoming earnings date is Mar 10, 2026, TBA (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateMar 10, 2026
Ex-Dividend Date―
Financial Position
Kuros Biosciences as a current ratio of 2.14, with Debt / Equity ratio of 2.34%
Current Ratio2.14
Quick Ratio1.69
Debt to Market Cap<0.01
Net Debt to EBITDA27.93
Interest Coverage Ratio-33.52
Taxes
In the past 12 months, Kuros Biosciences has paid 370.00K in taxes.
Income Tax370.00K
Effective Tax Rate-0.11
Enterprise Valuation
Kuros Biosciences EV to EBITDA ratio is -1.39K, with an EV/FCF ratio of 383.89.
EV to Sales10.30
EV to EBITDA-1.39K
EV to Free Cash Flow383.89
EV to Operating Cash Flow247.94
Balance Sheet
Kuros Biosciences has CHF17.90M in cash and marketable securities with CHF1.79M in debt, giving a net cash position of CHF16.11M billion.
Cash & Marketable SecuritiesCHF17.90M
Total DebtCHF1.79M
Net CashCHF16.11M
Net Cash Per ShareCHF0.41
Tangible Book Value Per ShareCHF0.65
Margins
Gross margin is 88.52%, with operating margin of -6.61%, and net profit margin of -4.92%.
Gross Margin88.52%
Operating Margin-6.61%
Pretax Margin-4.43%
Net Profit Margin-4.92%
EBITDA Margin-0.74%
EBIT Margin-4.23%
Analyst Forecast
The average price target for Kuros Biosciences is CHF36.62, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF36.62
Price Target Upside30.03% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast104.01%
EPS Growth Forecast33.25%